Sera Prognostics, Inc. (SERA) Financial Analysis & Valuation | Quarter Chart

Sera Prognostics, Inc., a women's health diagnostic company, discovers, develops, and commercializes biomarker tests for improving pregnancy outcomes. The company develops PreTRM test, a blood-based biomarker test to predict the risk of spontaneous preterm birth in asymptomatic singleton pregna... more
Sera Prognostics, Inc., a women's health diagnostic company, discovers, develops, and commercia... more

Company facts

Reported company information and share structure.

Company Share structure
Market Cap$79.63MExchangeNASDAQ
SectorHealthcareIndustryMedical - Diagnostics & Research
CountryUSCEOZhenya Lindgardt
IPO Date2021-07-15CAGR14.47%
Employees72Websiteseraprognostics.com
Div. YieldPayout Ratio
Buy Back YieldTotal Yield
SERA chart loading...

Key metrics

Reported fundamentals and market-derived technical indicators.

Fundamentals Technicals
EV$93.34MP/E-3.21Forward P/E-3.9PEG
P/S1610.69P/B2.5P/CF-5.37P/FCF-4.01
Sales$70,000Sales 1Y-35.19%Sales 3Y-81.33%Sales 5Y59.09%
EPS$-0.65EPS 1Y-21.18%EPS 3Y-48.85%EPS 5Y-33%
Sales QoQ114.29%EPS QoQ5.88%Sales QoQ Avg27.73%EPS QoQ Avg3.03%
Gross Margin-150%Operating Margin-53282.86%Profit Margin-47475.71%ROCE-59.79%
ROA-38%ROE-47%Altman Z Score-4.51Piotroski Score3
Current Ratio1.98Quick Ratio1.98Cash Ratio0.18Op. CF Ratio-0.26
Debt/Equity0.05Debt/Assets0.03Lt Debt/Equity0.05Lt Debt/Cap.
Intrst Cov.-5328.29Inventory TurnoverAsset Turnover0Receivables Turnover7
Enterprise Value$93.34MP/E Ratio-3.21
Forward P/E-3.9PEG Ratio
P/S Ratio1610.69P/B Ratio2.5
P/CF Ratio-5.37P/FCF Ratio-4.01
EPS$-0.65EPS Growth 1Y-21.18%
EPS Growth 3Y-48.85%EPS Growth 5Y-33%
Revenue Growth 1Y-35.19%Gross Margin-150%
Operating Margin-53282.86%Profit Margin-47475.71%
ROE-47%ROA-38%
ROCE-59.79%Current Ratio1.98
Quick Ratio1.98Cash Ratio0.18
Debt/Equity0.05Interest Coverage-5328.29
Altman Z Score-4.51Piotroski Score3